Early-stage breast cancer is defined as cancer that has not spread beyond the breast. If you have early-stage breast cancer,
you may be eligible for one of the following clinical trials offered at Albert Einstein Cancer Center:
B-29
B-29 is a clinical trial that will evaluate the effectiveness of the addition of octreotide to tamoxifen alone or to tamoxifen
and chemotherapy to improve the disease-free survival of patients with estrogen receptor positive tumors.
Octreotide is a long-acting somatostatin that can inhibit tumor growth as shown in scientific studies.
Tamoxifen has been used to treat breast cancer since it was first approved by the FDA in 1976. In 1998, additional studies
revealed that tamoxifen also prevents breast cancer recurrences in many women.
The B-29 clinical trial is open to women with primary invasive breast cancer who:
- have tumors that are estrogen receptor (ER) positive, and
- have no sign of cancer in the lymph nodes.
Primary invasive breast cancer is breast cancer that has the potential to spread. ER positive tumors are tumors known to be
responsive to hormonal therapy.
Based on the risk of recurrence for each individual participant, one of four treatments will be selected:
- tamoxifen alone;
- tamoxifen with octreotide;
- tamoxifen, octreotide and chemotherapy; or
- tamoxifen with chemotherapy.
B-29 is a study of the
National Surgical Adjuvant Breast and Bowel Project (NSABP).
For more information, please call (215) 456-7215.
B-30
B-30 is a clinical trial that will compare the effectiveness of three drug combinations in treating women with breast cancer
that has spread to, but not beyond, the axillary lymph nodes. Participants will be placed on one of the following three treatments
randomly.
- adriamycin and cyclophosphamide followed by taxotere;
- adriamycin and taxotere; and
- adriamycin, taxotere and cyclophosphamide.
To be eligible, women must:
- have no evidence of metastatic disease;
- have undergone either lumpectomy or total mastectomy plus axillary node dissection.
B-30 is a study of the
National Surgical Adjuvant Breast and Bowel Project (NSABP).
For more information, please call (215) 456-7215.
Back to Breast Cancer Studies
